Nachtigal M, Altman A, Arora R, Schweizer F, Arthur G
Cancers (Basel). 2022; 14(14).
PMID: 35884379
PMC: 9322924.
DOI: 10.3390/cancers14143318.
Wang T, Huynh K, Giles C, Mellett N, Duong T, Nguyen A
Alzheimers Dement. 2022; 18(11):2151-2166.
PMID: 35077012
PMC: 9787288.
DOI: 10.1002/alz.12538.
Berdel W, Danhauser S, Schick H, Hong 2nd C, West C, Fromm M
Lipids. 2016; 22(11):943-6.
PMID: 27519637
DOI: 10.1007/BF02535560.
Zhang M, Sun S, Tang N, Cai W, Qian L
Evid Based Complement Alternat Med. 2013; 2013:834027.
PMID: 23864898
PMC: 3705780.
DOI: 10.1155/2013/834027.
Iannitti T, Palmieri B
Mar Drugs. 2010; 8(8):2267-300.
PMID: 20948908
PMC: 2953404.
DOI: 10.3390/md8082267.
Antiproliferative Properties of Type I and Type II Interferon.
Bekisz J, Baron S, Balinsky C, Morrow A, Zoon K
Pharmaceuticals (Basel). 2010; 3(4):994-1015.
PMID: 20664817
PMC: 2907165.
DOI: 10.3390/ph3040994.
In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.
Brunton V, Workman P
Br J Cancer. 1993; 67(5):989-95.
PMID: 8388233
PMC: 1968438.
DOI: 10.1038/bjc.1993.181.
Effect of cell density on cytotoxicity of ether lipid analogues in variants of B16 murine melanoma.
Trulla L, Magistrelli A, Salmona M, Tacconi M
Lipids. 1993; 28(5):403-6.
PMID: 8316047
DOI: 10.1007/BF02535937.
Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.
Eue I, Zeisig R, Arndt D
J Cancer Res Clin Oncol. 1995; 121(6):350-6.
PMID: 7797600
DOI: 10.1007/BF01225687.
Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
Lohmeyer M, Workman P
Br J Cancer. 1995; 72(2):277-86.
PMID: 7640206
PMC: 2033967.
DOI: 10.1038/bjc.1995.325.
Alkyl-lysophospholipids inhibit the growth of hypernephroid carcinomas in vitro.
Berdel W, Fink U, Egger B, Reichert A, MUNDER P, Rastetter J
J Cancer Res Clin Oncol. 1981; 101(3):325-30.
PMID: 7309782
DOI: 10.1007/BF00410118.
Antineoplastic activity of synthetic lysophospholipid analogs.
Berdel W
Blut. 1982; 44(2):71-8.
PMID: 7059692
DOI: 10.1007/BF00320092.
Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.
Berdel W, Fink U, Maubach P, Permanetter B, Rastetter J
Blut. 1982; 44(3):177-86.
PMID: 6952952
DOI: 10.1007/BF00320765.
Antileukemic effect of alkyl phospholipids. II. Prolongation of survival times of leukemic mice by alkyl ethyleneglycophospholipids.
Honma Y, Kasukabe T, Okabe-Kado J, Hozumi M, Tsushima S, Nomura H
Cancer Chemother Pharmacol. 1983; 11(2):77-9.
PMID: 6578883
DOI: 10.1007/BF00254249.
Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship.
Berdel W, Von Hoff D, Unger C, Schick H, Fink U, Reichert A
Lipids. 1986; 21(4):301-4.
PMID: 3713449
DOI: 10.1007/BF02536417.
Immunomodulatory and therapeutic properties of alkyl lysophospholipids in mice.
Talmadge J, Schneider M, Lenz B, Phillips H, Long C
Lipids. 1987; 22(11):871-7.
PMID: 3502167
DOI: 10.1007/BF02535547.
Pharmacokinetics of the thioether phospholipid analogue BM 41.440 in rats.
Herrmann D, Besenfelder E, Bicker U, Pahlke W, Bohm E
Lipids. 1987; 22(11):952-4.
PMID: 3444391
DOI: 10.1007/BF02535562.
Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro.
Fromm M, Berdel W, Schick H, Fink U, Pahlke W, Bicker U
Lipids. 1987; 22(11):916-8.
PMID: 3444385
DOI: 10.1007/BF02535554.
Antitumor activity of synthetic alkylphospholipids with or without PAF activity.
Kudo I, Nojima S, Chang H, Yanoshita R, Hayashi H, Kondo E
Lipids. 1987; 22(11):862-7.
PMID: 3444379
DOI: 10.1007/BF02535545.
Ether lipids and analogs in experimental cancer therapy. A brief review of the Munich experience.
Berdel W
Lipids. 1987; 22(11):970-3.
PMID: 3328030
DOI: 10.1007/BF02535567.
